Compare the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Korean Patients With Left Ventricular Diastolic Dysfunction and Hyperlipidemia

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT04433533

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04433533
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04433533. Randomized; no masking; primary purpose treatment. Start 2021-01-06 (actual); primary completion 2023-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Compare the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Korean Patients With Left Ventricular Diastolic Dysfunction and Hyperlipidemia
Condition
Left Ventricular Diastolic Dysfunction
Condition
Hyperlipidemias
Intervention (Drug)
Rosuvastatin 20
Intervention (Drug)
Rosuvamibe 10/10
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct04433533
Content hash
12afc78ac0d0f0d00d5dbea620dd19c03d1115b75f76c2ef01450be72b12371d